Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from CVS Health ( (CVS) ) is now available.
On March 18, 2026, CVS Health’s board elected former Elevance Health chief financial officer John E. Gallina as a director, effective March 19, 2026, adding a veteran finance executive with nearly three decades of experience in health benefits and audit roles. Gallina, who also sits on the board of Arrive AI Inc. and several non-profit organizations, was deemed independent and appointed to CVS Health’s audit committee as an SEC-designated audit committee financial expert, with compensation aligned to other non-employee directors.
The most recent analyst rating on (CVS) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on CVS Health stock, see the CVS Stock Forecast page.
Spark’s Take on CVS Stock
According to Spark, TipRanks’ AI Analyst, CVS is a Neutral.
The score is held back primarily by sharply weakened profitability and a very high P/E valuation, despite solid cash generation. Reaffirmed 2026 guidance and operational improvements (notably Aetna and pharmacy momentum) provide support, while technical indicators point to mildly negative near-term momentum.
To see Spark’s full report on CVS stock, click here.
More about CVS Health
CVS Health is a diversified U.S. health care company operating in pharmacy services, retail health, and health insurance, with a focus on integrated care delivery and cost management across its national footprint. The company competes with major health insurers and pharmacy chains as it expands its role in managing patient care and medical benefits for a broad range of consumers and employers.
Average Trading Volume: 8,339,963
Technical Sentiment Signal: Buy
Current Market Cap: $92.9B
For detailed information about CVS stock, go to TipRanks’ Stock Analysis page.